Cystic fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Cystic fibrosis is caused by a defective gene. As a result, the internal organs, especially the lungs and digestive system, become clogged with thick sticky mucus resulting in chronic infections and inflammation in the lungs and difficulty digesting food. Find out more about what CF is and how it affects the body.
Around 10,800 people in the UK have cystic fibrosis; that's 1 in every 2,500 babies born. Cystic fibrosis affects around 100,000 people in the world.
Cystic fibrosis is a genetic condition. One person in 25 carries the faulty CF gene, usually without knowing; that's over two million people in the UK. If two carriers have a baby, the child has a one-in-four chance of having cystic fibrosis.
No, cystic fibrosis can't be caught or developed; it can only be caused by inheriting two copies of the faulty gene. You could be a gene carrier without having cystic fibrosis. Find out more about carrier testing in our factsheet (PDF).
Cystic fibrosis is also known as CF, mucovoidosis, or mucoviscidosis.
All newborn babies in the UK are now screened for cystic fibrosis shortly after birth using the heel-prick blood test. This tests for the most common mutations of the gene that causes cystic fibrosis.
Around one in 10 children with cystic fibrosis are diagnosed before, at, or shortly after birth, due to a condition called meconium ileus that causes the gut to become blocked with meconium - a thick, dark, sticky substance thatis made in all babies' intestines before being born. Urgent surgery may be needed to relieve the blockage.
Some children born earlier than 2007 who were not screened at birth, or those with more unusual mutations of the cystic fibrosis gene, may be diagnosed later in life, after they have become unwell and developed symptoms. Find out more about late diagnosis (PDF).
In people with cystic fibrosis the lungs make thicker sputum (mucus) than normal, which can trap bacteria in the small airways and lead to infection. Symptoms that typically develop include persistent cough, wheezing, shortness of breath and breathing difficulties and repeated chest infections. Find out more about how the lungs are affected.
Thickened mucus secretions block the normal flow of digestive juices from the pancreas, which means food can not be digested or absorbed properly, in particular fatty foods and fat-soluble vitamins (vitamins A, D, E and K). This can cause malnutrition, leading to poor growth and poor weight gain, a bloated abdomen and tummy aches, constipation and prolonged diarrhoea. Find out more about how the digestive system is affected.
Other symptoms can include sinus infections and nasal polyps. Some adults with cystic fibrosis may also get cystic fibrosis-related diabetes (CFRD), arthritis, osteoporosis and liver problems. Explore some of these other complications in more detail.
Symptoms usually first develop within the first year of life, but in a minority of cases may not appear until later in childhood or beyond. The severity of symptoms can vary and not all people with cystic fibrosis will have every symptom.
Take a look at our interactive body for more information on the symptoms of cystic fibrosis.
There are over 2,00 identified mutations of the cystic fibrosis gene. Cystic fibrosis is a very complex condition that affects people in different ways. Some suffer more with their digestive system than the lungs. Others have no problem with their pancreas.
Yes, cystic fibrosis is as common in both sexes.
Yes, cystic fibrosis affects people of many ethnic backgrounds, although it is more common in the Caucasian population.
It is misleading to suggest that there is an 'average life expectancy' that can be applied to everyone with cystic fibrosis. Life expectancy is likely to be different for people of different ages; and this is before taking into account the fact that CF can also affect people differently. The median predicted survival for someone with CF currently stands at 41 years old. This means that according to the statistics on the UK CF Registry, currently half of those with cystic fibrosis will live to over 41 years old, although a baby born today can be expected to live longer.
Day to day...
Cystic fibrosis affects everyone differently, but for many it involves a rigorous daily treatment regime including physiotherapy, oral, nebulised and occasionally intravenous antibiotics, and taking enzyme tablets with food. Some people with CF will have a feeding tube overnight. You can read more about each of these treatments in our factsheets.
For those who are very ill with cystic fibrosis and have very poor lung function, daily life can be a struggle as basic tasks can leave them breathless. Some patients use a wheelchair to get around and oxygen to help them breathe.
Children with cystic fibrosis should be encouraged to do things that their peers do, although there are a few things that should be avoided because they may harbour particular bugs which can cause problems for people with cystic fibrosis.
In most people with cystic fibrosis, the small channels that carry the digestive juices from the pancreas to the intestine become clogged with thick, sticky mucus. As a result, people with CF do not absorb and digest their food easily. This is called ‘pancreatic insufficiency’.
As well as taking enzyme pills to help digest food, most people with cystic fibrosis require 20% to 50% more calories each day than people without cystic fibrosis. Some may need considerably more. People with cystic fibrosis are encouraged to eat cakes, crisps, chocolate and other foods that are often considered 'unhealthy'. It is important to maintain a healthy weight as it helps the body deal more effectively with chest infections or weight loss caused by illness. Find out more about nutrition and cystic fibrosis.
Fertility, or the ability to have children, is usually normal or only slightly reduced in women, but most men with cystic fibrosis are infertile. This is due to an abnormality/absence of the vas deferens (the tube which carries sperm from the testis to the penis). The tubes are effectively blocked or absent altogether. Although sperm is produced and sexual function remains entirely normal, men with CF can seldom father children naturally.
However, recent advances in in-vitro fertilization and aspiration of sperm (extracting sperm directly from the testes) has allowed some men with cystic fibrosis to father children with clinical assistance. Some women with CF may be advised not to have children if their health is poor, as carrying a baby and giving birth could be detrimental to their health. Take a look at our resources around starting a family to find out more.
People with cystic fibrosis should not meet each other as they have different bacteria or 'bugs' that grow in their lungs. These 'bugs' are rarely harmful to those who do not have cystic fibrosis, but may be harmful to other people with the condition. We offer a forum for people with cystic fibrosis so they can interact safely. Find out more about cross-infection.
In England cystic fibrosis is currently not one of the medical conditions that makes people exempt from paying prescription charges. Currently people in Wales, Scotland and Northern Ireland do not pay prescription charges. Find out more about prescription charges.
Those with cystic fibrosis can be entitled to benefits. Find out more about how we may be able to assist you with applying for benefits.
As people with cystic fibrosis are living longer, healthier and more independent lives, many more are taking the opportunity to work part-or full-time. In the last report from the UK CF Registry, around 70% of those adults with cystic fibrosis who completed an employment questionnaire were in work or education.
There can be issues for people with cystic fibrosis in employment regarding time off or type of working environment. Find out more about employment.
Treatment and transplants
People with cystic fibrosis often have to undergo a rigorous daily regime of treatments to stay healthy. This can include taking inhaled and injected drugs to clear mucus and fight infections, taking dozens of enzyme pills to digest food and having physiotherapy morning and night. People with cystic fibrosis may also need a transplant. Lung transplants are the most common type for people with cystic fibrosis, as usually these are the organs most affected by cystic fibrosis. However, some people will have problems with their liver, kidneys or pancreas, and may need these organs transplanted.
Most babies with cystic fibrosis will need to start taking digestive enzymes straight away and will also begin physiotherapy to keep the lungs clear of mucus.
The majority of adults with cystic fibrosis go to one of the specialist CF centres in the UK. Children may have a shared-care arrangement, where they have some of their care at a local hospital and some at the nearest specialist CF centre, though the centre takes responsibility for their health.
It is vitally important that those with cystic fibrosis receive appropriate healthcare to ensure a better quality and length of life. Therefore, we strongly recommend that people with CF receive care from the multidisciplinary team of specialist doctors, nurses and allied health professionals at a recognised specialist CF centre. This includes specialist CF dietetic care and physiotherapy and should also provide psychosocial support.
Transplantation is only appropriate for a patient who is severely ill and for whom all other forms of conventional treatment are no longer helpful. Not all patients at this stage of the disease are suitable for a transplant and some patients may choose not to go on the transplant list.
It is important not to place too much emphasis on statistics when it comes to transplants, as some people sadly do not recover from a transplant and others are still thriving 10 years on, but the statistics show that around 70% of those with cystic fibrosis survive for five years post transplant.
We support any move that means more people with cystic fibrosis will have a chance of receiving a successful transplant.
Yes they can, as not all the organs are affected by cystic fibrosis.
Screening for cystic fibrosis
Yes, in some cases. Women can have amniocentesis or CVS to test the embryo for cystic fibrosis whilst pregnant. Occasionally, if the baby has meconium ileus (a bowel blockage commonly associated with cystic fibrosis) this can be picked up on an ultrasound scan and CF may be suspected.
Most people do not know if they are a carrier. If you have cystic fibrosis in your extended family, you should ask your GP to be tested as you are more likely to be a carrier than the general population. Download our carrier testing factsheet (PDF) to find out more.
Yes, since October 2007 all babies are offered screening for cystic fibrosis shortly after birth as part of the heel-prick blood test.
Pre-implantation Genetic Diagnosis (PGD) and Pre-implatantation Genetic Haplotyping (PGH) are ways in which two known carriers of the cystic fibrosis gene can have a baby without cystic fibrosis. Both techniques involve screening embryos conceived by IVF. However, whereas PGD tests for a specific mutation in a gene, PGH is able to identify a cystic fibrosis affected gene without needing to know the specific mutation.
We recognise that screening everyone to see if they are a carrier of the cystic fibrosis gene would be very expensive and impractical. However, we do recommend that anyone who is a blood relation of someone with cystic fibrosis is tested for carrier status.
Gene therapy and other research
Gene therapy is a way of treating or curing a disease by adding a copy of a healthy gene to do the job of a faulty one.
Gene therapy is not a cure for cystic fibrosis, but effective gene therapy could halt or prevent the lung damage that causes 90% of deaths of people with cystic fibrosis.
The Cystic Fibrosis Trust has invested over £30 million in gene therapy to date.
We funded the UK Gene Therapy Consortium (GTC) to develop a gene therapy product with the potential to 'correct' the faulty cystic fibrosis gene in the lungs. The GTC announced results from the Phase 2B clinical trials of its Wave 1 gene therapy product in 2015. The GTC are currently seeking a pharmaceutical partner to fund Phase 3 trials of the product, for which costs can be in excess of £100million.
Gene therapy would benefit most people with cystic fibrosis and works regardless of age as it replaces the faulty gene mutation with a correct version. Although it cannot reverse lung damage, it would stop the lungs from deteriorating further.
Stem cell therapy
Somatic cells (biological cells that form the body of an organism) are replenished from populations of stem cells, which have the unique ability to divide to produce both copies of themselves and other cell types.
Stem cells also have the ability to replace damaged cells in the body that would otherwise not be replenished. This property has led scientists to investigate the possible use of stem cells in regenerative medicine and the treatment of diseases. If you use gene therapy on stem cells, it is hoped that you will also correct the genetic fault in all the cells it reproduces. However, research into therapies using stem cells is still in its early stages.
There are two types of stem cells. The first are embryonic stem cells, which as their name suggests, are derived from embryos. The other is induced Pluripotent Stem Cells (iPS also called iPSC). These are created by taking a patient’s own mature cells (such as blood cells) and converting them back to become stem cells.
Stem cell therapy in the treatment of cystic fibrosis has not been approved for use in either Europe or America, and the treatment has not successfully undergone clinical trials.
A lot more basic information about stem cells and their behaviour is required before they can be used to develop treatments for cystic fibrosis. Scientists currently do not know the location of the stem cells that produce the cells in the lungs or whether stem cell transplants to the lung will even be possible. It is not yet known how transplanted stem cells will behave inside the body.
It is in the research strategy published in April 2013. We are funding research in the area of iPS.
We have provided a small grant to University of Cambridge for some preliminary laboratory based research, which involves genetic editing in iPS cells from people with CF.
Cystic fibrosis is a devastating condition so it is understandable that patients will seek new treatments to reduce the burden of the disease and prolong their life. However patients are advised that stem cell therapy recently reported in the news is unproven and has not undergone rigorous clinical trials so the risks of the treatment are currently unknown.
The treatment being carried out in the Dominican Republic has not been approved by the Regulatory Authorities in USA or Europe (FDA and EMA). It is unregulated and unproven and there is no approved scientific evidence that the procedure being undertaken in the Dominican Republic is safe or effective. The Trust would not encourage people living with cystic fibrosis to currently undertake any type of stem cell treatment in the UK or abroad.
Yes, but it must be combined with genetic editing. A lot more research is needed to help us understand how this would work to ensure its safety.
The Cystic Fibrosis Trust website carries up-to-date news of its latest research ventures so check it frequently. In addition, there is a stem cell catapult centre based at Guys Hospital. The Cell Therapy Catapult was established in 2012 as a centre of excellence in innovation, with the core purpose of building a world-leading cell therapy industry in the UK.
Questions about the Cystic Fibrosis Trust's research
We are the UK's only national charity dealing with all aspects of cystic fibrosis. We fund research to improve cystic fibrosis care and treatment, and aim to ensure appropriate clinical care and support for people with cystic fibrosis.
Ever since we began in 1964 we have funded research into every aspect of cystic fibrosis. Together with our national and international partners we continue to increase our understanding of cystic fibrosis and improve understanding, treatments and management of the condition.
We are also involved with social research, exploring the non-medical impact of cystic fibrosis, and its implications for quality and length of life.
Read more about our research.
Yes we do. We are a member of the Association of Medical Research Charities (AMRC), which recognises that a minimal amount of strictly controlled work using animals is essential to make progress in the treatment of life-threatening diseases. New medicines are legally required to use animals during development and safety-testing. Find out more about animals in research.
The Cystic Fibrosis Trust supports the right of scientists to use human and hybrid embryos in research into life-threatening conditions. However, at present we are not funding any research of this nature.
Research in cystic fibrosis takes place around the world in collaboration with specialist CF centres. Each CF centre may be involved in different areas of research at any point. This can be academic or clinical research and through the centre themselves, universities or pharmaceutical companies. Each CF centre will be able to give information on current trials and further information can be found on our clinical trials page. Europe-wide trials can be found on the ECFS Clinical Trials Network.
We received a one-off grant of £1 million from the Department of Health for our gene therapy research programme in 2007/8.
Yes, the cystic fibrosis community is a close-knit one and we have links with all the major cystic fibrosis charities and organisations worldwide.
From time to time we receive grants from pharmaceutical companies who have an interest in cystic fibrosis research, usually for specific things such as paying for the costs of a conference or for a particular publication. It will always be clearly indicated if we have received funding from a pharmaceutical company to help with one of our projects. The amount of funding received from pharmaceutical companies is small in relation to our overall income; last year it was roughly 0.5% of our total income.